Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBL-015 in Advanced Solid Tumors
NCT05153096Phase 1Not yet recruiting
- Sponsor
- NovaRock Biotherapeutics
- Start
- Apr 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NBL-015 in solid tumor, sponsored by NovaRock Biotherapeutics. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 8 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
NBL-015
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05153096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153096.